AAAAAA

   
Results: 1-10 |
Results: 10
ONCE-VERSUS TWICE-DAILY VENLAFAXINE THERAPY IN MAJOR DEPRESSION - A RANDOMIZED, DOUBLE-BLIND-STUDY
Authors: AMSTERDAM JD HOOPER MB AMCHIN J
Citation: Jd. Amsterdam et al., ONCE-VERSUS TWICE-DAILY VENLAFAXINE THERAPY IN MAJOR DEPRESSION - A RANDOMIZED, DOUBLE-BLIND-STUDY, The Journal of clinical psychiatry, 59(5), 1998, pp. 236-240
CLINICAL CONSIDERATIONS IN MANAGING NAUSEA ASSOCIATED WITH VENLAFAXINE
Authors: AMCHIN J ALBANO D
Citation: J. Amchin et D. Albano, CLINICAL CONSIDERATIONS IN MANAGING NAUSEA ASSOCIATED WITH VENLAFAXINE, Journal of clinical psychopharmacology, 17(6), 1997, pp. 489-490
EFFECT OF VENLAFAXINE ON THE PHARMACOKINETICS OF RISPERIDONE
Authors: AMCHIN J ZARYCRANSKI W TAYLOR K
Citation: J. Amchin et al., EFFECT OF VENLAFAXINE ON THE PHARMACOKINETICS OF RISPERIDONE, Psychopharmacology bulletin, 33(3), 1997, pp. 491-491
VENLAFAXINES LOW DRUG-INTERACTION POTENTIAL BASED ON CYTOCHROME-P450 - IN-VIVO EVIDENCE CONFIRMING IN-VITRO DATA OF LOW CYP2D6 AND NO CYP3A4 INHIBITION
Authors: AMCHIN J ALBANO D TROY S ERESHEFSKY L
Citation: J. Amchin et al., VENLAFAXINES LOW DRUG-INTERACTION POTENTIAL BASED ON CYTOCHROME-P450 - IN-VIVO EVIDENCE CONFIRMING IN-VITRO DATA OF LOW CYP2D6 AND NO CYP3A4 INHIBITION, Psychosomatics, 38(2), 1997, pp. 212-212
VENLAFAXINES LACK OF CYP3A4 INHIBITION ASSESSED BY TERFENADINE METABOLISM
Authors: AMCHIN J ZARYCRANSKI W TAYLOR K
Citation: J. Amchin et al., VENLAFAXINES LACK OF CYP3A4 INHIBITION ASSESSED BY TERFENADINE METABOLISM, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 56-56
EVIDENCE THAT VENLAFAXINE DOES NOT INHIBIT CYP1A2 AS MEASURED IN-VIVOBY THE METABOLISM OF CAFFEINE
Authors: AMCHIN J ZARYCRANSKI W TAYLOR K
Citation: J. Amchin et al., EVIDENCE THAT VENLAFAXINE DOES NOT INHIBIT CYP1A2 AS MEASURED IN-VIVOBY THE METABOLISM OF CAFFEINE, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 57-57
POTENTIAL HAZARD OF SEROTONIN SYNDROME-ASSOCIATED WITH DEXFENFLURAMINE HYDROCHLORIDE (REDUX) - REPLY
Authors: DOLAN JA AMCHIN J ALBANO D
Citation: Ja. Dolan et al., POTENTIAL HAZARD OF SEROTONIN SYNDROME-ASSOCIATED WITH DEXFENFLURAMINE HYDROCHLORIDE (REDUX) - REPLY, JAMA, the journal of the American Medical Association, 276(15), 1996, pp. 1220-1221
EFFECT OF VENLAFAXINE ON THE PHARMACOKINETICS OF ALPRAZOLAM
Authors: AMCHIN J ZARYCRANSKI W
Citation: J. Amchin et W. Zarycranski, EFFECT OF VENLAFAXINE ON THE PHARMACOKINETICS OF ALPRAZOLAM, Psychopharmacology bulletin, 32(3), 1996, pp. 410-410
RELATIONSHIP OF PLASMA-CONCENTRATIONS OF FLUOXETINE AND VENLAFAXINE WITH EFFECTS ON CYP2D6 IN-VIVO
Authors: ERESHEFSKY L AMCHIN J ZARYCRANSKI W HEATH G
Citation: L. Ereshefsky et al., RELATIONSHIP OF PLASMA-CONCENTRATIONS OF FLUOXETINE AND VENLAFAXINE WITH EFFECTS ON CYP2D6 IN-VIVO, Psychopharmacology bulletin, 32(3), 1996, pp. 440-440
CLARIFICATION OF VENLAFAXINE CHEMISTRY, PHARMACOLOGY, AND PHARMACOKINETICS
Authors: ALBANO D AMCHIN J
Citation: D. Albano et J. Amchin, CLARIFICATION OF VENLAFAXINE CHEMISTRY, PHARMACOLOGY, AND PHARMACOKINETICS, American journal of health-system pharmacy, 52(14), 1995, pp. 1573-1573
Risultati: 1-10 |